-+ 0.00%
-+ 0.00%
-+ 0.00%

Estrella Immunopharma reports 10,000-fold reduction in leukemia burden in preclinical ARTEMIS studies

PUBT·11/16/2026 13:01:32
Listen to the news
Estrella Immunopharma reports 10,000-fold reduction in leukemia burden in preclinical ARTEMIS studies
  • Estrella Immunopharma will present preclinical ARTEMIS T-cell therapy findings at the American Society of Hematology meeting on December 12, 2026.
  • ARTEMIS produced faster, deeper leukemia responses than conventional CAR-T cells in animal models, including complete regression of established disease outside bone marrow.
  • The findings support development of lead candidate EB103, currently in the STARLIGHT-1 Phase I/II trial for B-cell non-Hodgkin lymphoma.
  • Clinical evaluation is needed to determine whether the preclinical benefits translate into improved patient outcomes.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Estrella Immunopharma Inc. published the original content used to generate this news brief via Business Wire (Ref. ID: 20261116987637) on November 16, 2026, and is solely responsible for the information contained therein.